Advertisement
Research Article

Multiple Sources of Contamination in Samples from Patients Reported to Have XMRV Infection

  • Mary F. Kearney mail,

    kearneym@mail.nih.gov

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Jonathan Spindler,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Ann Wiegand,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Wei Shao,

    Affiliation: Advanced Biomedical Computing Center, SAIC, Frederick, Maryland, United States of America

    X
  • Elizabeth M. Anderson,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Frank Maldarelli,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Francis W. Ruscetti,

    Affiliation: Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • John W. Mellors,

    Affiliation: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    X
  • Steve H. Hughes,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Stuart F. J. Le Grice,

    Affiliation: HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • John M. Coffin

    Affiliation: Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, United States of America

    X
  • Published: February 20, 2012
  • DOI: 10.1371/journal.pone.0030889

About the Authors

Mary F. Kearney, Jonathan Spindler, Ann Wiegand, Elizabeth M. Anderson, Frank Maldarelli, Steve H. Hughes, Stuart F. J. Le Grice
HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
Wei Shao
Advanced Biomedical Computing Center, SAIC, Frederick, Maryland, United States of America
Francis W. Ruscetti
Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute, Frederick, Maryland, United States of America
John W. Mellors
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
John M. Coffin
Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, United States of America

Corresponding Author

Email: kearneym@mail.nih.gov

Competing Interests

Dr. Mellors is a consultant for Gilead Sciences, Merck, and RFS Pharma and owns share options in RFS Pharma. Dr. Shao is an employee of SIAC, Frederick. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: MK JMC. Performed the experiments: MK AW JS FR. Analyzed the data: MK JS AW JMC WS EA. Contributed reagents/materials/analysis tools: FM SL FR. Wrote the paper: MK JMC JWM SH.